Estimating the Size of a first dose-The case of a new anti-hypertensive drug (AHD)

2015 ◽  
Keyword(s):  
Hypertensive Drug

Does Increased Platelet Release Normalize During Anti-Hypertensive Treatment?

1987 ◽  
Vol 58 (03) ◽  
pp. 834-838
Author(s):  
Knut Lande ◽  
Sverre Erik Kjeldsen ◽  
Ivar Eide ◽  
Paul Leren ◽  
Knut Gjesdal
Keyword(s):  
Platelet Function ◽  
Adrenergic Receptor ◽  
Blood Platelet ◽  
Placebo Treatment ◽  
Sampling Procedure ◽  
Β Blocker ◽  
Platelet Release ◽  
Hypertensive Drug ◽  
Second Period ◽  
Release Product

SummaryBlood platelet function was evaluated in 10 men, all 50 years old, with untreated, mild hypertension. Each patient was examined four times: At the beginning of the study, after 5 weeks on placebo treatment, after the following 5 weeks on propranolol 160 mg daily, and finally after a second period of 5 weeks on placebo. At baseline the plasma level of the platelet release product (β-thromboglobulin (BTG) was 41.6 (30.5-57.0) μg/l (median and 95% confidence interval). During the first placebo period BTG was normalized to 21.0 (14.1-25.9) μg/l. While systolic blood pressure and heart rate fell during β-adrenergic receptor blockade, BTG remained unchanged throughout the rest of the observation periods. Platelet size increased significantly during treatment with β-blocker. The present study indicates that the normalization of elevated platelet function which previously has been reported to occur during anti-hypertensive drug therapy, may be explained by patient adaptation to the blood sampling procedure.

scholarly journals Knowledge about hypertension and factors associated with the non-adherence to drug therapy

2014 ◽  
Vol 22 (3) ◽  
pp. 491-498 ◽  
Author(s):  
Mayckel da Silva Barreto ◽  
Annelita Almeida Oliveira Reiners ◽  
Sonia Silva Marcon
Keyword(s):  
Drug Therapy ◽  
Healthcare Service ◽  
Cross Sectional Study ◽  
Medication Regimen ◽  
Cross Sectional ◽  
Poor Knowledge ◽  
Factors Associated ◽  
Medication Regimen Complexity ◽  
Hypertensive Drug ◽  
Complex Drug

OBJECTIVES: to identify the degree of knowledge of people with hypertension concerning the disease and to verify the factors associated with the non-adherence to anti-hypertensive drug therapy.METHOD: Cross sectional study, involving 422 people. Data collection took place at their homes, between December 2011 and March 2012, through interviews using the following instruments: Medication Adherence Questionnaire (MAQ-Q), Medication Regimen Complexity Index (MRCI) and a guide with questions related to sociodemographic profile, satisfaction with healthcare service and knowledge about the disease.RESULTS: 42.6% did not adhere to the drug therapy and 17.7% had poor knowledge about the disease. Factors associated with the non-adherence were: complex drug therapy, poor knowledge about the disease and dissatisfaction with the healthcare service.CONCLUSION: The findings reinforce that the complex drug therapy prescriptions, little knowledge about the disease and dissatisfaction with the healthcare service have influence on the process of non-adherence to anti-hypertensive drug therapy.

Biodegradable Chitosan-g-Poly(methacrylamide) Microspheres for Controlled Release of Hypertensive Drug

2012 ◽  
Vol 21 (4) ◽  
pp. 1128-1134 ◽  
Author(s):  
Bala Yerri Swamy ◽  
Chavidi Venkata Prasad ◽  
M. N. Prabhakar ◽  
Kashay Chowdoji Rao ◽  
M. C. S. Subha ◽  
...  
Keyword(s):  
Controlled Release ◽  
Hypertensive Drug

scholarly journals Redefining the role of Ca2+-permeable channels in photoreceptor degeneration using diltiazem

2022 ◽  
Vol 13 (1) ◽  
Author(s):  
Soumyaparna Das ◽  
Valerie Popp ◽  
Michael Power ◽  
Kathrin Groeneveld ◽  
Jie Yan ◽  
...  
Keyword(s):  
Cell Death ◽  
Retinal Degeneration ◽  
Photoreceptor Cell ◽  
Strong Increase ◽  
Channel Blockers ◽  
Photoreceptor Degeneration ◽  
Therapy Development ◽  
Hypertensive Drug ◽  
Future Therapy

AbstractHereditary degeneration of photoreceptors has been linked to over-activation of Ca2+-permeable channels, excessive Ca2+-influx, and downstream activation of Ca2+-dependent calpain-type proteases. Unfortunately, after more than 20 years of pertinent research, unequivocal evidence proving significant and reproducible photoreceptor protection with Ca2+-channel blockers is still lacking. Here, we show that both D- and L-cis enantiomers of the anti-hypertensive drug diltiazem were very effective at blocking photoreceptor Ca2+-influx, most probably by blocking the pore of Ca2+-permeable channels. Yet, unexpectedly, this block neither reduced the activity of calpain-type proteases, nor did it result in photoreceptor protection. Remarkably, application of the L-cis enantiomer of diltiazem even led to a strong increase in photoreceptor cell death. These findings shed doubt on the previously proposed links between Ca2+ and retinal degeneration and are highly relevant for future therapy development as they may serve to refocus research efforts towards alternative, Ca2+-independent degenerative mechanisms.

scholarly journals Sacubitril/valsartan Inhibits Obesity-associated Diastolic Dysfunction through Suppression of Ventricular-vascular Stiffness

2021 ◽  
Author(s):  
Annayya R Aroor ◽  
Srinivas Mummidi ◽  
Juan Carlos Lopez-Alvarenga ◽  
Nitin Das ◽  
Javad Habibi ◽  
...  
Keyword(s):  
Arterial Stiffness ◽  
Diastolic Dysfunction ◽  
Left Ventricular ◽  
Vascular Stiffness ◽  
Saline Control ◽  
Preclinical Model ◽  
Cardiovascular Protection ◽  
Group 5 ◽  
Group 2 ◽  
Hypertensive Drug

Abstract Objective: Both cardiac diastolic dysfunction (DD) and arterial stiffness are early manifestations of obesity-associated prediabetes and serve as risk factors for the development of heart failure with preserved ejection fraction (HFpEF). Since the incidence of DD and arterial stiffness are increasing worldwide due to exponential growth in obesity, an effective treatment is urgently needed to blunt their development and progression. Here we investigated whether the combination of an inhibitor of neprilysin (sacubitril), a natriuretic peptide-degrading enzyme, and an angiotensin II type 1 receptor blocker (valsartan), suppresses DD and arterial stiffness in an animal model of prediabetes more effectively than valsartan monotherapy.Methods: Sixteen week-old male Zucker Obese rats (ZO; n=64) were assigned randomly to 4 different groups: Group 1: saline control (ZOC); Group 2: sacubitril/valsartan (sac/val; 68 mg•kg-1•day-1; ZOSV); Group 3: valsartan (31 mg•kg-1•day-1; ZOV) and Group 4: hydralazine, an anti-hypertensive drug (30 mg•kg-1•day-1; ZOH). Six Zucker Lean (ZL) rats that received saline only (Group 5) served as lean controls (ZLC). Drugs were administered daily for 10 weeks by oral gavage.Results: Sac/val improved echocardiographic parameters of impaired left ventricular (LV) stiffness in untreated ZO rats, without altering the amount of food consumed or body weight gained. In addition to improving DD, sac/val also decreased aortic stiffness and reversed impairment of nitric oxide-induced vascular relaxation seen in ZO rats. However, sac/val had no impact on LV hypertrophy. Notably, sac/val was more effective at ameliorating DD compared to val. Although, hydralazine was as effective as sac/val in improving these parameters, it adversely affected LV mass index. Further, proteomics revealed distinct effects of sac/val, including marked suppression of Notch-1 by both valsartan and sac/val suggesting that cardiovascular protection afforded by both share some common mechanisms; however, sac/val increased IL-4 which is increasingly been recognized for its cardiovascular protection, possibly contributing, in part, to more favorable effects of sac/val over val alone in improving obesity associated DD.Conclusions: These studies suggest that sac/val is superior to val in reversing obesity-associated DD. It is an effective drug combination to blunt progression of asymptomatic DD and vascular stiffness to HFpEF development in a preclinical model of obesity-associated prediabetes.

scholarly journals Unresponsive shock due to amlodipine overdose: An unexpected cause

2018 ◽  
Vol 10 (4) ◽  
pp. 246-247 ◽  
Author(s):  
Shailesh Kumar ◽  
Devyani Thakur ◽  
Ritesh Kumar Gupta ◽  
Alka Sharma
Keyword(s):  
Channel Blocker ◽  
Kidney Injury ◽  
Poor Performance ◽  
Interesting Case ◽  
Young Lady ◽  
Fluid Replacement ◽  
Refractory Shock ◽  
Shock Reversal ◽  
Dihydropyridine Calcium Channel Blocker ◽  
Hypertensive Drug

Amlodipine is a dihydropyridine calcium channel blocker which is widely used as an anti-hypertensive drug. Amlodipine overdose has been infrequently reported with the occurrence of serious complications and even death in a few cases. We report an interesting case of a young lady who presented with refractory shock with acute kidney injury, which did not respond to therapy despite optimal fluid replacement and vasopressor support. The etiology of shock could not be ascertained and the patient was questioned again to elucidate the missing clue in the history. It was finally revealed that the patient had consumed 900 mg of amlodipine in a suicide bid, for her poor performance in academics. The targeted therapy in the form of IV calcium and hyperinsulinemia-euglycemia therapy (HIET) was started and the patient dramatically improved with shock reversal and improvement in renal function.

Role of Alpha Adrenoceptors in Hypertension and in Anti hypertensive Drug Treatment

1984 ◽  
Vol 77 (4) ◽  
pp. 17-25 ◽  
Author(s):  
P.A. Van Zwieten ◽  
P.B.M.W.M. Timmermans ◽  
P. Van Brummelen
Keyword(s):  
Drug Treatment ◽  
Alpha Adrenoceptors ◽  
Hypertensive Drug

scholarly journals EFFECTS OF ANTI-HYPERTENSIVE DRUG CLASSES ON 24-HOUR PULSE PRESSURE AMPLIFICATION

2019 ◽  
Vol 37 ◽  
pp. e312-e313
Author(s):  
G. Pucci ◽  
M. Maggi ◽  
B. Hametner ◽  
S. Wassertheurer ◽  
A. Cerasari ◽  
...  
Keyword(s):  
Pulse Pressure ◽  
Pressure Amplification ◽  
Drug Classes ◽  
Hypertensive Drug
Sign in / Sign up

Export Citation Format

Share Document